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Role of Epstein-Barr virus in transformation of follic-
ular lymphoma to diffuse large B-cell lymphoma: a
case report and review of the literature
The Epstein-Barr virus (EBV) is the most common
human virus, implicated in the pathogenesis of several
human tumors, particularly B-cell lymphomas.1 EBV-
induced lymphoproliferative disorders are the result of
the outgrowth of EBV-infected B cells that would normal-
ly be controlled by an effective EBV-specific cytotoxic 
T-cell response.2,3 The association between EBV and fol-
licular lymphoma (FL) is not well recognized and only ten
cases have been previously described.4-7 Nine of them
showed EBV-encoded small RNA (EBER)-positivity in
>75% of the tumor cells and one case in ~5–10%. EBV-
positivity was associated with grade 3 FL (9/10 cases),
CD30 expression and rapid progression of disease.6
However, it is still unclear whether EBV infection is an
early event in the development of FL or a late event that
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Figure 1. Histological examination of the 2017 specimen.
(A-C) Effacement of the nodal architecture and cellular
necrosis (A) with areas of grade 2 follicular lymphoma (B)
intermingled with a diffuse proliferation of blastic elements
(C) were seen. (D,E) The neoplastic cells of the follicular
component expressed BCL-2 (D) as did the diffuse compo-
nent (E). Fluorescence in situ hybridization using break-
apart probes was positive for the BCL2 translocation in
both the follicular (inset 1D) and diffuse (inset 1E) areas.
(F,G) Positivity for LMP-2A and EBV-encoded RNA in situ
hybridization was present in scattered neoplastic cells with-
in the follicles of the follicular areas (F) and in 90% of the
neoplastic cells in the diffuse areas (G).
Immunohistochemistry for Zebra was also positive in scat-
tered larger cells in the diffuse areas (inset 1G). Original
magnification: (A) 2.5x; (B-E) 10x; (F,G) 20x.
A
B C
D E
F G
may contribute to the progression of a pre-existing lym-
phoma. We describe a case of EBV-positive diffuse large
B-cell lymphoma (DLBCL) that evolved from a previous
FL. In April 2011, a 73-year old woman presented with
systemic lymphadenopathy and a history of weakness. A
right inguinal lymph node was removed for histological
examination which showed complete effacement of the
nodal architecture by closely packed follicles, with atten-
uated mantle zones, loss of polarity and absence of tingi-
ble body macrophages. The tumor cells expressed CD20,
CD10, BCL-2, BCL-6 and, focally, CD30. The prolifera-
tion index (Ki-67) was about 20%. Fluorescence in situ
hybridization using break-apart probes identified the typ-
ical BCL2 translocation. Due to the involvement of mul-
tiple extranodal sites, a diagnosis of FL, grade 2, stage IVA
(Ann Arbor system) was made. The patient was treated
with four cycles of rituximab plus fludarabine, mitox-
antrone, and dexamethasone, followed by maintenance
therapy (rituximab). The treatment was discontinued in
2013 because the disease was progressing. Biopsy of a
right axillary lymph node was performed, confirming the
previous diagnosis with an increased proliferative index
(40%). The patient was placed in a "watch and wait" pro-
gram. In March 2016, a follow-up computed tomography
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Figure 2. B-cell clonality, an identical N-
glycosylation motif and Epstein-Barr
virus positivity were demonstrated in all
the specimens. (A,B) Laser capture
microdissection of the follicular and dif-
fuse areas of the 2017 lymph node biop-
sy. (C,D) A peak of 316 base pairs (bp) in
length was identified in both the follicu-
lar and diffuse components. (E,F) EBV-
encoded RNA in situ hybridization was
positive in the 2011 and 2013 follicular
lymphoma samples of the patient,
increasing from the first (5%) to the sec-
ond (10%) biopsy. (G,H) The clonal analy-
sis of the 2011 and 2013 follicular lym-
phoma samples identified a peak with
the same length as that of the 2017
sample (316 bp). (I) The corresponding
FR1-JH polymerase chain reaction prod-
ucts of all the samples were directly
sequenced and a productive IGH-VDJ
rearrangement (V1-18*01, D3-9*01
and J4*02) with 86.76% homology with
the germ-line sequence was detected,
confirming the clonal relationship. (J)
Furthermore, in all the biopsies, we
detected an identical somatic hypermu-
tation pattern and the same N-glycosyla-
tion motif (NTT) in the HCDR3 region,
characteristic of follicular lymphoma.
Original magnification: (A,B,E,F) 10x. FL:
follicular lymphoma; DLBCL: diffuse
large B-cell lymphoma.
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scan revealed enlargement of mediastinal and abdominal
lymph nodes and laboratory tests showed increased
serum lactate dehydrogenase levels. The patient started
the rituximab plus cyclophosphamide, vincristine and
prednisolone protocol which was interrupted in March
2017 because of pulmonary intolerance. A new regimen
with rituximab and fludarabine per os was started. In
November 2017, the patient was hospitalized for recur-
rent non-infectious fever and a left inguinal-crural lymph
node biopsy was performed. Histological examination
showed the presence of a diffuse proliferation of large
lymphoid cells intermingled with areas of FL grade 2 and
areas of necrosis (Figure 1A-C). The neoplastic cells of
both components expressed PAX-5, CD10, BCL-2, BCL-
6, MUM-1 and CD30. The proliferative index was 70%
in the areas of diffuse proliferation. Fluorescence in situ
hybridization using break-apart probes identified the
BCL2 translocation in both areas (Figure 1D,E). Ninety
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Figure 3. Time trend of evolution of the tumor
microenvironment evolution. (A-D) In the follic-
ular lymphoma sample, the neoplastic follicles
showed a low number of regulatory T cells
(A,B) and exhausted T cells (C). Numerous M2
macrophages were also found in the interfollic-
ular areas accompanied by occasional M2
macrophages expressing PD-L1 (D). (E-H) The
diffuse large B-cell lymphoma biopsy showed
increased regulatory T cells (E,F) and exhaust-
ed T cells (G). The number of M2 macrophages
was increased and the great majority of them
expressed PDL-1 (H). PD-L1 expression was
also demonstrated in scattered neoplastic
cells by double staining with PAX-5 and PD-L1
(H inset). Original magnification: (A-H) 20x.
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percent of the neoplastic cells in the diffuse area and scat-
tered cells in the follicular area were positive for Epstein-
Barr latent membrane protein (LMP)-2A and EBER in situ
hybridization (Figure 1F,G). A diagnosis of DLBCL trans-
formed from FL was proposed. Due to the patient’s criti-
cal clinical condition and high viral loads of
cytomegalovirus (32,461 copies) and EBV (24,212 copies)
in the serum, the patient was treated with rituximab and
lenalinomide plus valgancyclovir for the cytomegalovirus
infection. To evaluate whether we were dealing with the
transformation of the pre-existing FL, a comparative eval-
uation of the original FL and DLBCL specimens was
made in terms of clonality, EBV status and tumor
microenvironment. To assess B-cell clonality, IGH-VDJ
rearrangements were studied in all the specimens accord-
ing to the BIOMED-2 protocol. Specifically, to evaluate
whether the EBV-positive population observed in the his-
tological sections of DLBCL corresponded to the follicu-
lar population, we performed laser capture microdissec-
tion of the diffuse and follicular areas of the 2017 biopsy
(Figure 2A,B). A peak of 316 base pairs (bp) in length was
identified in both (Figure 2C,D). We then checked the
EBV status also in the 2011 and 2013 FL samples and
found the virus in 5% (2011) and 10% (2013) of neoplas-
tic cells within the follicles (Figure 2E,F). After laser cap-
ture microdissection, the clonal analysis of the 2011 and
2013 FL samples identified a peak with the same length
as the 2017 one (316 bp) (Figure 2G,H). The correspon-
ding FR1-JH polymerase chain reaction (PCR) products of
all the samples were directly sequenced and a productive
IGH-VDJ rearrangement (V1-18*01, D3-9*01 and J4*02)
with 86.76% homology of the germline sequence was
detected, confirming the clonal relationship (Figure 2I).
Furthermore, in all the biopsies, we detected an identical
somatic hypermutation pattern and the same N-glycosy-
lation motif (NTT) in the HCDR3 region (Figure 2J). Since
the oncogenic role of EBV in leading the transformation
of FL to a high-grade form is still controversial, a com-
plete genetic assessment of the virus latency by quantita-
tive reverse transcription PCR and immunohistochem-
istry was performed. The expression of EBV nuclear anti-
gen (EBNA)-1 and the negativity for LMP-1 and EBNA-2
in the FL specimen suggested a type I latency. In the
DLBCL sample, we detected a non-canonical latency pat-
tern of neoplastic cells characterized by the expression of
LMP-2A along with some genes/proteins involved in the
lytic cycle [BMRF1/Ea-D, BHRF1/Ea-R/p17 and
BZLF1/Zebra (Figure 1G inset)]. Finally, we studied the
tumor microenvironment of the FL and DLBCL speci-
mens to identify a possible alteration of the EBV-host bal-
ance responsible for the evolution. In the FL sample, the
neoplastic follicles showed a low number of regulatory T
cells (CD4+/FOXP3+ and CD25+/FOXP3+/CTLA-4+)
(Figure 3A,B) and CD8+/PD1+/Granzyme B+ T cells
(Figure 3C). The scenario was different in the trans-
formed DLBCL biopsy, which showed increased regula-
tory and CD8+/PD1+/Granzyme B+ T cells (Figure 3E-G).
The latter were concentrated at the periphery of the
necrotic areas; the center of the necrotic area showed a
significant increase of CD8+ T cells. In the FL sample
numerous CD163+/c-MAF+ macrophages (M2
macrophages) were found in the interfollicular areas
accompanied by occasional CD163+/PD-L1+ cells (Figure
3D). In DLBCL, the M2 macrophages increased and the
great majority expressed PD-L1 (Figure 3H). PD-L1
expression was also demonstrated in scattered neoplastic
cells  (Figure 3H inset).
The patient’s clinical condition worsened and she died
in June 2018.
The process of transformation has some confounding
factors: the impact of chemotherapy on the immune
microenvironment; the role of the immune system; the
proliferative advantage provided by EBV; the impact of
EBV latency program modification and expression of
additional EBV products; and the natural evolution of FL
independently of EBV. Our case favors the hypothesis
that EBV was the trigger responsible for the transforma-
tion of FL in DLBCL, under permissive immunological
conditions. Indeed, the evidence of EBV lytic cycle reac-
tivation in the DLBCL sample and the expression of a
non-canonical latency program, as demonstrated by
quantitative reverse transcription PCR and immunhisto-
chemistry, may shed light on the effective role of the
virus in the transformation of the disease and in the
maintenance of an immunosuppressive niche.
Conventionally, EBV-driven lymphomagenesis is
thought to involve primarily the latent cycle, but there is
increasing evidence that lytic gene products contribute to
the development and maintenance of malignancies
through the induction of growth factors, oncogenic
cytokine production such as interleukin-10, transforming
growth factor-β9-11 and the evasion of the inflammatory
response by attenuation of interferon-g.12 Furthermore,
we were able to demonstrate the clonal relationship
between the diffuse areas and follicular components in all
three biopsies and direct sequencing of the FR1-JH PCR
products showed an identical IGH-VDJ rearrangement.
These findings were also consolidated by the identifica-
tion of an identical somatic hypermutation pattern and
the same NTT which are characteristic of FL and uncom-
mon in other B-cell malignancies.8
The role of the virus in the transformation is further
supported by the changes induced in the tumor microen-
vironment. In fact, a valuable CD4/PD-1 T-cell popula-
tion controls the response against the virus in the follicu-
lar components.2 Following chemotherapy, the balance
between EBV and the host immune system might have
been disrupted leading to unchecked EBV activation
resulting in non-canonical latency of the virus in the
DLBCL sample and changes in the inflammatory
microenvironment.9 In fact, in the diffuse areas, we found
an increased number of T-regulatory cells and
CD8+/PD1+/Granzyme B+ T cells as well as the expres-
sion of PD-L1 on M2 macrophages and lymphoid cells.
The PD-1/PD-L1 pathway is a key check-point in con-
trolling the re-education of the tumor
microenvironment,13 diminishing activation of tumor
infiltrating lymphocytes and inhibiting phagocytosis and
tumor immunity, promoting lymphoma growth.14 This
pattern seems to be different from EBV-negative DLBCL
in which the number of M2 macrophages expressing PD-
L1 is lower than in our case (preliminary, unpublished
results from Marafioti et al.).
Notwithstanding this evidence, the precise role of EBV
lytic activity and its ability to reshape the tumor microen-
vironment remains elusive and further investigation is
warranted. However, our findings expand the spectrum
of recognized EBV-associated B-cell lymphomas and raise
the question as to whether EBV association should be
investigated in cases of FL to establish its relationship
with lymphomagenesis or transformation.
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